- Home
- MNMD vs IIIV Comparison
MNMD vs IIIV Comparison
Compare MNMD & IIIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNMD
- IIIV
- Stock Information
- Founded
- MNMD 2019
- IIIV 2012
- Country
- MNMD United States
- IIIV United States
- Employees
- MNMD N/A
- IIIV N/A
- Industry
- MNMD Pharmaceuticals and Biotechnology
- IIIV EDP Services
- Sector
- MNMD Health Care
- IIIV Technology
- Exchange
- MNMD Nasdaq
- IIIV Nasdaq
- Market Cap
- MNMD 509.2M
- IIIV 707.2M
- IPO Year
- MNMD N/A
- IIIV 2018
- Fundamental
- Price
- MNMD $7.85
- IIIV $28.24
- Analyst Decision
- MNMD Strong Buy
- IIIV Buy
- Analyst Count
- MNMD 7
- IIIV 7
- Target Price
- MNMD $26.29
- IIIV $29.57
- AVG Volume (30 Days)
- MNMD 1.2M
- IIIV 419.9K
- Earning Date
- MNMD 08-12-2025
- IIIV 08-07-2025
- Dividend Yield
- MNMD N/A
- IIIV N/A
- EPS Growth
- MNMD N/A
- IIIV 4907.14
- EPS
- MNMD N/A
- IIIV 4.75
- Revenue
- MNMD N/A
- IIIV $241,651,000.00
- Revenue This Year
- MNMD N/A
- IIIV N/A
- Revenue Next Year
- MNMD N/A
- IIIV $5.74
- P/E Ratio
- MNMD N/A
- IIIV $5.93
- Revenue Growth
- MNMD N/A
- IIIV 5.59
- 52 Week Low
- MNMD $4.70
- IIIV $20.42
- 52 Week High
- MNMD $10.44
- IIIV $30.10
- Technical
- Relative Strength Index (RSI)
- MNMD 61.23
- IIIV 59.73
- Support Level
- MNMD $6.95
- IIIV $28.57
- Resistance Level
- MNMD $8.11
- IIIV $30.10
- Average True Range (ATR)
- MNMD 0.41
- IIIV 0.99
- MACD
- MNMD 0.12
- IIIV 0.24
- Stochastic Oscillator
- MNMD 85.27
- IIIV 67.65
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
About IIIV i3 Verticals Inc.
i3 Verticals Inc offers integrated payment and software solutions to small and medium-sized businesses and organizations in strategic vertical markets. Its operating segment includes Public Sector and Healthcare. The company generates maximum revenue from the Public Sector segment.